期刊文献+

非霍奇金淋巴瘤靶向治疗新进展 被引量:2

下载PDF
导出
摘要 肿瘤分子靶向治疗,是指在细胞分子水平上,针对已经明确的致癌位点(该位点可以是肿瘤细胞内部的一个蛋白分子,也可以是一个基因片段),来设计相应的治疗药物,药物进入体内以后靶向性选择与这些致癌位点相结合并发生作用,导致肿瘤细胞特异性死亡,而较少作用于肿瘤周围的正常组织细胞,所以分子靶向治疗又被称为“生物导弹”。分子靶向治疗的问世,不仅改变了传统化疗药物治疗模式,而且提高了某些肿瘤治愈率。根据药物的作用靶点和性质不同,本文就目前非霍奇金淋巴瘤中靶向治疗及其进展作一综述。
出处 《浙江临床医学》 2010年第3期323-325,共3页 Zhejiang Clinical Medical Journal
  • 相关文献

参考文献23

  • 1Colombat P, Salles G, Brousse N, et al. Rituximab ( anti - CD20 monoclonal antibody) as single first - line therapy for patients with follicula lymphoma with a low tumor burden : clinical and molecular evaluation. Blood,2001,97:101 - 106.
  • 2Czuczman MS, Fallon A, Mohr A, et al. Phase Ⅱ study of rituximab plus fludarabine in patients (pts.) with low -grade lymphoma. Blood ,2001,98 (Suppl 1 ) :601 (Abstr 2518A ).
  • 3王迎,李业楠,邹德慧,王亚非,秦铁军,赵耀中,钱林生,邱录贵.美罗华联合化疗治疗侵袭性B细胞非霍奇金淋巴瘤的临床分析[J].中国肿瘤临床,2008,35(8):421-423. 被引量:11
  • 4Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood,2004,104:2269 - 2271.
  • 5Leonard JP, Morion C, Jamie CK, et al. Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non - Hedgkin' s Lymphoma. J Clin Ontol,2005,23(22) :5044 -5051.
  • 6Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34 - containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood ,2000,96:864 - 869.
  • 7Vose JM,Wahl RL, Saleh M, et al. Muhicenter phase Ⅱ study of io- dine - 1 3 1 tositumomab for chemotherapy - relapsed/refractory lowgradeand transformed low - grade B - cell non - Hod gkin' s lymphomasJ Clin Oncol,2000,18 (6) : 1316 - 1323.
  • 8Kaminski MS,Zelenetz AD, Press OW, et al. Pivotal study of iodine - 131 tositumomab for chemotherapy - refractory low - grade or transformed low - grade B - cell non - Hodgkin' s lymphomas. J Clin Oncol,2001,19:3918 - 3928.
  • 9Cruczman MS, Thall A, Witzig TE, et al. Phase Ⅰ/Ⅱ study of galiximab, an anti - CD80 antibody for relapsed or refractoryfollicular lymphoma. J Clin Oneol,2005 ,23 :4390 -4398.
  • 10Leonard JP, Friedberg JW. Durable Responses in Patients Treated with Galiximab ( Anti - CD80 ) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long - Term Follow - up of a Phase Ⅱ Clinical Trial. Blood. Nov,2008,112:1004.

二级参考文献9

  • 1赵耀中,邹德慧,李睿,王亚非,万长春,王国蓉,麦玉洁,李桥川,李云涛,靳风艳,徐燕,林华,钱林生,邱录贵.47例晚期非霍奇金淋巴瘤临床分析及治疗策略的探讨[J].白血病.淋巴瘤,2004,13(4):195-197. 被引量:5
  • 2陆文斌,金建华,顾小燕,王芳,李献文,张华,杨玉薇.CHOPE方案治疗侵袭性非霍奇金淋巴瘤(NHL)40例[J].中国肿瘤临床,2007,34(3):151-153. 被引量:9
  • 3李妍,王迎,邹德慧,傅明伟,赵耀中,李新,王国蓉,邓书会,邱录贵.HyperCVAD/MA方案强化治疗31例淋巴系统肿瘤的初步临床观察[J].国际输血及血液学杂志,2007,30(2):122-127. 被引量:11
  • 4Stern M,Herrmann R. Overview of monodonal antibodies in cancer therapy: present and promise[J]. Crit Rev Oncol Hematol, 2005, 54(1): 11-29
  • 5Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monodonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase Ⅱ study [J]. Blood, 1998, 92(6): 1927-1932
  • 6Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cydophosphamide, doxorubicin, vincristine, and predrtisone significandy improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)[J].J Clin Oncol, 2005, 23(9): 1984-1992
  • 7Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mande-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine[J].J Clin Oncol, 2005, 23 (28): 7018-7028
  • 8Jermann M, Jost LM, Tavema CA, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed,refractory or transformed B-cell lymphomas: results of a phase H study [J]. Ann Oncol, 2004, 15(3): 511-516
  • 9Berinstein NL. Principles of maintenance therapy [J]. Leuk Res, 2006, 30(Suppl 1): S3-S10

共引文献10

同被引文献37

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部